

 EndoGastric Solutions. **March 14, 2011**

ENDOGASTRIC SOLUTIONS RECOGNIZED IN WALL STREET JOURNAL'S "NEXT BIG THING" TOP 50 VENTURE CAPITAL- FUNDED COMPANIES RANKED THIRD AMONG MEDICAL DEVICE COMPANIES

REDWOOD CITY, CA – EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced today that it has received the distinction of being named one of the Wall Street Journal's "The Next Big Thing" Top 50 venture capital-funded companies in America. EndoGastric Solutions was the third highest ranking medical device company and one of only eight health care companies recognized in the list. The list, published yesterday, identifies organizations demonstrating the "greatest promise to succeed."

To be eligible, companies must have received an equity round of financing in the past three years and be valued at less than \$1 Billion. Over 5,000 eligible companies were ranked on five criteria:

- The track record of success for the venture-capital investors who sit on the company's board
- The amount of capital raised by the company over past three years
- Dow Jones Venture Wire editorial ranking
- The track record of success for the entrepreneurial CEO and founders
- The recent growth in value of the company

"We are honored to be named as one of America's most promising venture-backed companies by the Wall Street Journal," commented Thierry Thauré, President and

Press Release

Chief Executive Officer of EndoGastric Solutions. "Our future success will be a result of our ability to develop innovative technologies, teach safe and effective procedures, and partner with surgeons and hospitals in building patient awareness. We are proud to receive this distinction, but the real honor is the ability to improve the lives of tens of millions of patients around the world."

About EndoGastric Solutions®

EndoGastric Solutions, Inc. is a pioneer in endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders. EGS' mission is to utilize the most current wisdom in gastroenterology and surgery to develop new incisionless, transoral procedures and products to address the largest unmet needs in gastrointestinal diseases.

For more information about EndoGastric Solutions and its products, EsophyX® and StomaphyX®, please visit:

<http://www.endogastricsolutions.com/>

View TIF EsophyX video animation

View the GERDHelp.com website, providing patient information on the symptoms and causes of GERD, as well as the treatment options available for it, including the incisionless TIF procedure.